One mechanism for the current clinical treatment of ERBB2-positive breast cancer with the ERBB2 antibody Herceptin/Trastuzumab (and possibly others) may be due to autophagy inhibition by the antibody-induced ERBB2 degradation and ATG12 downregulation. The gene discussed is ERBB2; the disease is breast cancer.